This series features essays by Dr. Kenneth Serbin, Professor of History, originally posted on his blog, At Risk for Huntington's Disease."
Huntington's Disease (HD) is a genetically caused brain disorder that causes uncontrollable bodily movements and robs people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
Blog Posts from 2018
Roche announces first sites for key Huntington’s disease observational study, Kenneth P. Serbin
Unpacking GENERATION HD1, the Roche Phase 3 Huntington's disease clinical trial, Kenneth P. Serbin
Roche Phase 3 clinical trial for Huntington’s disease gene-slicing drug to enroll volunteers in early 2019, Kenneth P. Serbin
In Harriet’s tragic death, the vulnerability caused by Huntington's disease – but also the story of a beautiful soul, Kenneth P. Serbin
Free from the threat of Huntington’s disease, our 'miracle baby' turns 18, Kenneth P. Serbin
New Ionis data show positive trends in clinical measures of Huntington's disease drug trial volunteers, Kenneth P. Serbin
Nora Guthrie: we’re all ‘hoping machines’ in the fight against Huntington's disease, Kenneth P. Serbin
Roche gears up for pivotal Phase 3 Huntington’s disease gene-slicing clinical trial, Kenneth P. Serbin
In chronicling the quest to cure Huntington’s disease, a whirlwind of emotions, Kenneth P. Serbin
The best news for the Huntington's disease community since the discovery of the gene: Ionis trial data revealed, Roche confirms jump to Phase 3, Kenneth P. Serbin
Overflow audience at 13th annual Huntington's Disease Therapeutics Conference, Kenneth P. Serbin
CHDI's 13th conference promises some good news for the Huntington's disease community, Kenneth P. Serbin
Faith in each other: sticking together through the challenges of Huntington's disease, Kenneth P. Serbin
Blog Posts from 2017
Ionis scientists provide initial assessment of successful Phase 1/2a Huntington's disease trial and discuss next steps, Kenneth P. Serbin
Ionis drug successfully reduces toxic Huntington’s disease protein, paving way for Phase 2 trial of effect on patients, Kenneth P. Serbin
A time for hope: HDSA’s 50th anniversary, a record-setting gala, and the impending release of highly anticipated clinical trial results, Kenneth P. Serbin
Advocacy in the workplace: raising awareness about Huntington's disease and brain health, Kenneth P. Serbin
Ionis Huntington’s disease drug a step closer to a critical Phase 2 study, Kenneth P. Serbin
Join the Facebook Live event (soon!) on Pope Francis's historic audience with Huntington's disease families, Kenneth P. Serbin
Francis made a day of ‘superlatives’ for the Huntington's disease community, says event co-organizer, Kenneth P. Serbin
Pope Francis declares: Huntington’s disease should be 'hidden no more', Kenneth P. Serbin
Fear not, Huntington’s disease families – Pope Francis has our backs, Kenneth P. Serbin
Preparing for the meeting with Pope Francis, a heartening milestone in the Huntington's disease movement, Kenneth P. Serbin
Pope Francis I to meet with victims of Huntington’s disease, a first for a world leader, Kenneth P. Serbin
Staying when the Chargers leave: a leading Huntington's disease advocate sets a gutsy, loving example, Kenneth P. Serbin